Same Source Kang Medicine - B (02410.HK) announced its interim performance as of the end of June, with no recorded revenue during the period. The loss widened to 0.219 billion yuan, compared to a loss of 0.174 billion yuan in the same period last year. The loss per share was 0.68 yuan. No dividend will be paid. The company's research and development costs during the period reached 0.138 billion yuan, an increase of 15.3% year-on-year, while administrative expenses increased by 80.8% to 40.1 million yuan.